Cosentyx(secukinumab)
Cosentyx (secukinumab) is an antibody pharmaceutical. Secukinumab was first approved as Cosentyx on 2015-01-14. It is used to treat ankylosing spondylitis and psoriatic arthritis in the USA. It has been approved in Europe to treat ankylosing spondylitis, psoriasis, and psoriatic arthritis. The pharmaceutical is active against interleukin-17A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| musculoskeletal diseases | D009140 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Cosentyx (discontinued: Cosentyx)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cosentyx | Biologic Licensing Application | 2026-04-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psoriatic arthritis | EFO_0003778 | D015535 | L40.5 |
| ankylosing spondylitis | EFO_0003898 | D013167 | M45 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
266 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 9 | 11 | 43 | 21 | 31 | 114 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | 1 | 5 | 15 | 4 | 16 | 41 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 2 | 8 | 16 | 4 | 8 | 37 |
| Spondylarthritis | D025241 | — | — | — | 3 | 15 | 5 | 4 | 27 |
| Spondylitis | D013166 | — | M46.9 | — | 2 | 14 | 5 | 4 | 25 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 3 | 9 | 6 | 4 | 22 |
| Hidradenitis suppurativa | D017497 | — | L73.2 | 1 | — | 3 | 2 | 16 | 22 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 5 | 3 | 1 | 2 | 11 |
| Axial spondyloarthritis | D000089183 | — | — | — | — | 5 | 2 | 3 | 10 |
| Healthy volunteers/patients | — | — | — | 5 | 1 | — | 1 | — | 6 |
Show 28 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | 1 | 1 | 2 | — | 3 | 7 |
| Polymyalgia rheumatica | D011111 | EFO_0008518 | M35.3 | 1 | 3 | 3 | — | — | 7 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | 1 | 6 | — | — | 7 |
| Giant cell arteritis | D013700 | EFO_1001209 | M31.6 | 1 | 3 | 2 | — | — | 6 |
| Hidradenitis | D016575 | — | — | 1 | — | 2 | — | 3 | 6 |
| Dermatitis | D003872 | — | L30.9 | — | 2 | 2 | — | — | 4 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | 1 | 3 | — | — | 4 |
| Vasculitis | D014657 | EFO_0006803 | M31 | — | 2 | 2 | — | — | 4 |
| Lupus nephritis | D008181 | EFO_0005761 | — | — | — | 2 | — | — | 2 |
| Nephritis | D009393 | — | N05 | — | — | 2 | — | — | 2 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 3 | — | — | — | 3 |
| Sclerosis | D012598 | — | — | — | 3 | — | — | — | 3 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 2 | — | — | 1 | 3 |
| Pyoderma gangrenosum | D017511 | EFO_0006835 | L88 | 1 | 2 | — | — | — | 2 |
| Pyoderma | D011711 | — | L08.0 | 1 | 2 | — | — | — | 2 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 2 | — | — | — | 2 |
| Eczema | D004485 | — | L30.9 | — | 1 | — | — | 1 | 2 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 2 | — | — | — | 2 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | 1 | — | — | 1 | 2 |
| Intestinal diseases | D007410 | — | K63.9 | — | 1 | — | — | 1 | 2 |
Show 24 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pityriasis rubra pilaris | D010916 | — | L44.0 | 1 | — | — | — | — | 1 |
| Pityriasis | D010915 | — | — | 1 | — | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | — | — | — | 1 | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 1 | 1 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 1 | 1 |
| Blood platelet disorders | D001791 | — | — | — | — | — | — | 1 | 1 |
| Hemostatic disorders | D020141 | — | — | — | — | — | — | 1 | 1 |
| Coagulation protein disorders | D020147 | — | — | — | — | — | — | 1 | 1 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | — | — | 1 | 1 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Secukinumab |
| INN | secukinumab |
| Description | Secukinumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743068 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09029 |
| UNII ID | DLG4EML025 (ChemIDplus, GSRS) |
Target
Agency Approved
IL17A
IL17A
Organism
Homo sapiens
Gene name
IL17A
Gene synonyms
CTLA8, IL17
NCBI Gene ID
Protein name
interleukin-17A
Protein synonyms
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, cytotoxic T-lymphocyte-associated protein 8, interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8), interleukin-17
Uniprot ID
Mouse ortholog
Il17a (16171)
interleukin-17A (Q62386)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Cosentyx – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
162,070 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use